PMID- 38331912
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240214
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 15
IP  - 1
DP  - 2024 Feb 8
TI  - Assessment of human leukocyte antigen-based neoantigen presentation to determine 
      pan-cancer response to immunotherapy.
PG  - 1199
LID - 10.1038/s41467-024-45361-5 [doi]
LID - 1199
AB  - Despite the central role of human leukocyte antigen class I (HLA-I) in tumor 
      neoantigen presentation, quantitative determination of presentation capacity 
      remains elusive. Based on a pooled pan-cancer genomic dataset of 885 patients 
      treated with immune checkpoint inhibitors (ICIs), we developed a score 
      integrating the binding affinity of neoantigens to HLA-I, as well as HLA-I allele 
      divergence, termed the HLA tumor-Antigen Presentation Score (HAPS). Patients with 
      a high HAPS were more likely to experience survival benefit following ICI 
      treatment. Analysis of the tumor microenvironment indicated that the antigen 
      presentation pathway was enriched in patients with a high HAPS. Finally, we built 
      a neural network incorporating factors associated with neoantigen production, 
      presentation, and recognition, which exhibited potential for differentiating 
      cancer patients likely to benefit from ICIs. Our findings highlight the clinical 
      utility of evaluating HLA-I tumor antigen presentation capacity and describe how 
      ICI response may depend on HLA-mediated immunity.
CI  - (c) 2024. The Author(s).
FAU - Han, Jiefei
AU  - Han J
AUID- ORCID: 0000-0003-4686-2530
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
AD  - Department of Neuro-oncology, Neurosurgery Center, Beijing Tiantan Hospital, 
      Capital Medical University, Beijing, China.
FAU - Dong, Yiting
AU  - Dong Y
AUID- ORCID: 0000-0003-0850-031X
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Zhu, Xiuli
AU  - Zhu X
AUID- ORCID: 0000-0001-6313-686X
AD  - Geneplus-Beijing Institute, Beijing, China.
AD  - University of Chinese Academy of Sciences, Beijing, 100049, China.
AD  - CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of 
      Genomics, Chinese Academy of Sciences and China National Center for 
      Bioinformation, Beijing, 100101, China.
FAU - Reuben, Alexandre
AU  - Reuben A
AUID- ORCID: 0000-0003-4510-0382
AD  - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. 
      D. Anderson Cancer Center, Houston, Texas, USA.
FAU - Zhang, Jianjun
AU  - Zhang J
AUID- ORCID: 0000-0001-7872-3477
AD  - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. 
      D. Anderson Cancer Center, Houston, Texas, USA.
FAU - Xu, Jiachen
AU  - Xu J
AUID- ORCID: 0000-0003-4565-6364
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Bai, Hua
AU  - Bai H
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Duan, Jianchun
AU  - Duan J
AUID- ORCID: 0000-0003-3300-1707
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Wan, Rui
AU  - Wan R
AUID- ORCID: 0000-0002-7177-7736
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Zhao, Jie
AU  - Zhao J
AUID- ORCID: 0000-0003-0728-8548
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China.
FAU - Bai, Jing
AU  - Bai J
AD  - Geneplus-Beijing Institute, Beijing, China.
FAU - Xia, Xuefeng
AU  - Xia X
AD  - Geneplus-Beijing Institute, Beijing, China.
FAU - Yi, Xin
AU  - Yi X
AD  - Geneplus-Beijing Institute, Beijing, China.
FAU - Cheng, Chao
AU  - Cheng C
AUID- ORCID: 0000-0002-5002-3417
AD  - Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Institute for 
      Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, 
      USA. Chao.Cheng@bcm.edu.
FAU - Wang, Jie
AU  - Wang J
AUID- ORCID: 0000-0002-5602-0487
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China. zlhuxi@163.com.
FAU - Wang, Zhijie
AU  - Wang Z
AUID- ORCID: 0000-0002-7722-4956
AD  - State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational 
      Research on Lung Cancer, Department of Medical Oncology, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, 
      China. wangzj@cicams.ac.cn.
LA  - eng
GR  - 81871889/National Natural Science Foundation of China (National Science 
      Foundation of China)/
PT  - Journal Article
DEP - 20240208
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - *Neoplasms/drug therapy/genetics
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Antigens, Neoplasm
MH  - Histocompatibility Antigens Class II
MH  - HLA Antigens/genetics
MH  - Immunotherapy
MH  - Tumor Microenvironment
PMC - PMC10853168
COIS- The authors declare no competing interests.
EDAT- 2024/02/09 00:42
MHDA- 2024/02/11 07:19
PMCR- 2024/02/08
CRDT- 2024/02/08 23:42
PHST- 2023/03/17 00:00 [received]
PHST- 2024/01/19 00:00 [accepted]
PHST- 2024/02/11 07:19 [medline]
PHST- 2024/02/09 00:42 [pubmed]
PHST- 2024/02/08 23:42 [entrez]
PHST- 2024/02/08 00:00 [pmc-release]
AID - 10.1038/s41467-024-45361-5 [pii]
AID - 45361 [pii]
AID - 10.1038/s41467-024-45361-5 [doi]
PST - epublish
SO  - Nat Commun. 2024 Feb 8;15(1):1199. doi: 10.1038/s41467-024-45361-5.